Combined blockade of early and late activated atrial potassium currents suppresses atrial fibrillation in a pig model of obstructive apnea

Heart Rhythm

Volumn 8, Issue 12, 2011, Pages 1933-1939

  Linz, Dominik ^a,b   Schotten, Ulrich ^b   Neuberger, Hans Ruprecht ^a   Böhm, Michael ^a   Wirth, Klaus ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Antiarrhythmia agents; Atrial fibrillation; Electrophysiology; Obstructive sleep apnea; Potassium channel

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; AMIODARONE; POTASSIUM CHANNEL; SOTALOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIAL EFFECTIVE REFRACTORY PERIOD; DRUG EFFECT; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART CYCLE; HEART ELECTROPHYSIOLOGY; MALE; NEGATIVE TRACHEAL PRESSURE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; SLEEP APNEA SYNDROME; SWINE; TRACHEA PRESSURE;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; MALE; MODELS, ANIMAL; POTASSIUM; POTASSIUM CHANNELS, VOLTAGE-GATED; SLEEP APNEA, OBSTRUCTIVE; SOTALOL; SWINE;

EID: 82455208938     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2011.07.018     Document Type: Article

References (32)

1. A.S. Gami, G. Pressman, and S.M. Caples Association of atrial fibrillation and obstructive sleep apnea Circulation 110 2004 364 367
2. A.S. Gami, D.O. Hodge, and R.M. Herges Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation J Am Coll Cardiol 49 2007 565 571
3. A.S. Gami, and V.K. Somers Implications of obstructive sleep apnea for atrial fibrillation and sudden cardiac death J Cardiovasc Electrophysiol 19 2008 997 1003
4. D. Patel, P. Mohanty, and L. Di Biase Safety and efficacy of pulmonary vein antral isolation in patients with obstructive sleep apnea: the impact of continuous positive airway pressure Circ Arrhythm Electrophysiol 3 2010 445 451
5. K. Jongnarangsin, A. Chugh, and E. Good Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation J Cardiovasc Electrophysiol 19 2008 668 672
6. M. Matiello, M. Nadal, and D. Tamborero Low efficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients Europace 12 2010 1084 1089
7. R. Kanagala, N.S. Murali, and P.A. Friedman Obstructive sleep apnea and the recurrence of atrial fibrillation Circulation 107 2003 2589 2594
8. D. Linz, U.Neuberger H.R.Böhm M. Schotten, and K. Wirth Negative tracheal pressure during obstructive respiratory events promotes atrial fibrillation by vagal activation Heart Rhythm 8 2011 1436 1443
9. T. Kasai, and T.D. Bradley Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications J Am Coll Cardiol 57 2011 119 127
10. J.M. Parish, and V.K. Somers Obstructive sleep apnea and cardiovascular disease Mayo Clin Proc 79 2004 1036 1046
11. M. Kohler, and J.R. Stradling Mechanisms of vascular damage in obstructive sleep apnea Nat Rev Cardiol 7 2010 677 685
12. U. Schotten, S. Verheule, P. Kirchhof, and A. Goette Pathophysiological mechanisms of atrial fibrillation: a translational appraisal Physiol Rev 91 2011 265 325
13. H. Gogelein, J. Brendel, and K. Steinmeyer Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels Naunyn Schmiedebergs Arch Pharmacol 370 2004 183 192
14. S. Nattel Antiarrhythmic drug classifications A critical appraisal of their history, present status, and clinical relevance Drugs 41 1991 672 701
15. P. Gautier, E. Guillemare, and L. Djandjighian In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects J Cardiovasc Pharmacol 44 2004 244 257
16. K.J. Wirth, and K. Knobloch Differential effects of dofetilide, amiodarone, and class lc drugs on left and right atrial refractoriness and left atrial vulnerability in pigs Naunyn Schmiedebergs Arch Pharmacol 363 2001 166 174
17. K. Mori, Y. Hara, T. Saito, Y. Masuda, and H. Nakaya Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells Different molecular mechanisms Circulation 91 1995 2834 2843
18. Y. Watanabe, Y. Hara, M. Tamagawa, and H. Nakaya Inhibitory effect of amiodarone on the muscarinic acetylcholine receptor-operated potassium current in guinea pig atrial cells J Pharmacol Exp Ther 279 1996 617 624
19. E. Guillemare, A. Marion, D. Nisato, and P. Gautier Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells J Cardiovasc Pharmacol 36 2000 802 805
20. R.A. Navarro-Polanco, and J.A. Sanchez-Chapula 4-aminopyridine activates potassium currents by activation of a muscarinic receptor in feline atrial myocytes J Physiol 498 1997 663 678
21. H. Shi, H. Wang, and Z. Wang Identification and characterization of multiple subtypes of muscarinic acetylcholine receptors and their physiological functions in canine hearts Mol Pharmacol 55 1999 497 507
22. H. Shi, H. Wang, D. Li, S. Nattel, and Z. Wang Differential alterations of receptor densities of three muscarinic acetylcholine receptor subtypes and current densities of the corresponding K+ channels in canine atria with atrial fibrillation induced by experimental congestive heart failure Cell Physiol Biochem 14 2004 31 40
23. A. Pleumsamran, and D. Kim Membrane stretch augments the cardiac muscarinic K+ channel activity J Membr Biol 148 1995 287 297
24. K. Knobloch, J. Brendel, S. Peukert, B. Rosenstein, A.E. Busch, and K.J. Wirth Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide Naunyn Schmiedebergs Arch Pharmacol 366 2002 482 487
25. M. Courtemanche, R.J. Ramirez, and S. Nattel Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model Cardiovasc Res 42 1999 477 489
26. M. Duytschaever, Y. Blaauw, and M. Allessie Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs Cardiovasc Res 67 2005 69 76
27. M.C. Wijffels, R. Dorland, and M.A. Allessie Pharmacologic cardioversion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: a comparison between hydroquinidine, cibenzoline, flecainide, and d-sotalol J Cardiovasc Electrophysiol 10 1999 178 193
28. Y. Blaauw, H. Gogelein, R.G. Tieleman, A. van Hunnik, U. Schotten, and M.A. Allessie "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat Circulation 110 2004 1717 1724
29. Y. Blaauw, U. Schotten, A. van Hunnik, H.R. Neuberger, and M.A. Allessie Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat Cardiovasc Res 75 2007 89 98
30. D.K. Linz, F. Afkham, G. Itter, H. Rutten, and K.J. Wirth Effect of atrial electrical remodeling on the efficacy of antiarrhythmic drugs: comparison of amiodarone with I(Kr)- and I(to)/I(Kur)-blockade in vivo J Cardiovasc Electrophysiol 18 2007 1313 1320
31. M.C. Wijffels, C.J. Kirchhof, R. Dorland, J. Power, and M.A. Allessie Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation Circulation 96 1997 3710 3720
32. S.V. Pandit, S. Zlochiver, and D. Filgueiras-Rama Targeting atrioventricular differences in ion channel properties for terminating acute atrial fibrillation in pigs Cardiovasc Res 89 2011 843 851